*	OR T2 T4
R4	Has_temporal Arg1:T7 Arg2:T11	
R6	AND Arg1:T16 Arg2:T14	
R7	Has_multiplier Arg1:T18 Arg2:T19	
R8	Has_temporal Arg1:T18 Arg2:T20	
R10	Has_temporal Arg1:T22 Arg2:T23	
*	OR T14 T15
*	OR T3 T1
R1	AND Arg1:T2 Arg2:T3	
*	OR T7 T8 T9 T10
R2	Has_index Arg1:T11 Arg2:T13	
R3	Has_index Arg1:T20 Arg2:T21	
T1	Drug 82 95	GLP-1 analogs
T2	Observation 21 31	this study
T4	Observation 47 62	any other study
T3	Drug 69 78	exenatide
T7	Observation 122 136;175 180	interventional study
T8	Observation 138 145;175 180	medical study
T9	Observation 147 155;175 180	surgical study
T10	Observation 160 180	pharmaceutical study
T11	Temporal 181 208	within 30 days of screening
T14	Drug 249 258	metformin
T15	Drug 262 274	sulfonylurea
T16	Condition 216 248	characteristics contraindicating
T18	Drug 304 321	exogenous insulin
T19	Multiplier 322 342	for more than 1 week
T20	Temporal 343 381	within the 3 months prior to screening
T22	Drug 394 415	drugs for weight loss
T23	Temporal 416 443	within 1 month of screening
T13	Reference_point 199 208	screening
T21	Reference_point 372 381	screening
